Scientists have developed a new assay to test for various tumor indicators in bladder cancer.

Methylation specific-multiplex ligation-dependent probe amplication (MS-MLPA) can be utilized to screen multiple target sequences concurrently in a single reaction, permitting for fast early screening of tumor markers.

But, commercially available MS-MLPA kits are not available for many illnesses, and custom probe design has been limited by troubles of chemically synthesizing longer nucleotides.

Scientists from the Danish Cancer Society and the Herlev University Hospital of Copenhagen have now altered this assay by making use of multiple short synthetic probes to examine for tumor markers in bladder cancer.

Dr. Per Guldberg of the Danish Cancer Society and colleagues, Study's lead author, discovered that paired tumor and urine samples in the majority of cases showed identical marker patterns, suggesting that this assay may be utilized for non-invasive diagnosis and disease monitoring. (With Inputs from Agencies)